Future studies will be necessary to determine whether PTEN, SHIP1, and INPP4B up-regulation in stem cells is associated with specific clinical features in patients with MDS and whether these phosphatases could be used as biomarkers to select patients for specific therapeutic approaches. This evidence concerns the gene INPP4B and myelodysplastic syndrome.